The Munich-based non-profit patient association LeukaNET e.V. is looking for a Scientific Engagement Manager / Project Manager who will help manage and drive cancer patient engagement in initiatives like the EU HARMONY Alliance as well as scientific projects of the patient community in Chronic Myeloid Leukemia. Want to spend your life on something for a purpose? Check this out!
Position: Scientific Engagement Manager / Project Manager
Contract: Full-time / permanent
Location: Munich (mainly home office, plus our office in Giesing)
Start: immediately / as soon as possible
Salary: 40.000 EUR gross per annum
The Scientific Engagement Manager / Project Manager will primarily be responsible for the management, engagement and content development mainly of the following initiatives:
The tasks are subject to change depending on needs of the organisation and the projects.
LeukaNET e.V. is a non-profit association established in Munich, Germany, in 2003. Its roots and main activities are running the patient-run, independent virtual patient community leukaemie-online.de for leukaemia patients and their families in German-speaking countries. Its goals are to support patients and their carers by providing background information and news about research, treatment and care as well as to run and moderate discussion forum, social media channels, online seminars and patient meetings.
With its mission to strengthen patient-centric clinical research and collaboration of the patient community with researchers, LeukaNET e.V. collaborates very closely with patient organisations and research organisations all across the world. LeukaNET is a co-founder of the CML Advocates Network. It collaborates closely e.g. with the German CML Study Group and is a steering committee member of the German CML Alliance. It is a consortium member and work package leader of the European research projects IMI HARMONY and IMI HARMONY-PLUS.
The Big Data For Better Outcomes Programme is an umbrella programme of the Innovative Medicines Initiative 2 (IMI2). IMI2 is a collaboration between the European Union and European Federation of Pharmaceutical Industries and Associations (EFPIA) and is the world’s largest public-private partnership (PPP) in the life sciences which funds more than 140 EU projects.
The HARMONY Alliance, consisting of the EU-funded IMI projects HARMONY (2017-2022) and the HARMONY-PLUS (2020-2023), helps improve the prognosis and outcome of patients with hematological cancers, driven by knowledge derived from the combination and analysis of complex data. Therefore, a core part of HARMONY is its Patient Cluster, which is currently made up of 7 pan-European patient organizations. Each of these organizations represents the 7 blood cancers HARMONY is researching. The HARMONY Patient Cluster plays an important role in designing research projects to make sure they reflect the patient view. The patient cluster is currently being extended.
The CML Advocates Network is an active network specifically for leaders of Chronic Myeloid Leukemia (CML) patient groups, connecting 126 patient organisations in 93 countries on all continents. It was set-up and is run by CML patients and carers. Its aim is to facilitate and support best practice sharing among patient advocates across the world.
The CML Community Advisory Board (CML-CAB) is a working group of the CML Advocates Network. It is a global panel of 18 leading patient advocates from all world regions (“CML-CAB members”) who all speak from the unique perspective of a CML patient or relative. CML-CAB members work together to address issues of strategic importance to the community and advocate for the best possible research and equal access to the most innovative treatment & care for CML patients around the world. CML-CAB monitors pharmaceutical developments and research in CML through active and targeted interaction, long-term cooperation and continued dialogue with pharmaceutical partners, regulators, medical experts, and the scientific CML-community.